Published in Br J Cancer on September 04, 2012
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | NCT00831480
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma | NCT00827359
High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. PLoS One (2015) 0.85
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer (2013) 0.83
Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol (2013) 0.82
Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression. PLoS One (2015) 0.81
Targeted Therapy for Metastatic Renal Carcinoma: an Update. J Kidney Cancer VHL (2014) 0.75
Preoperative serum docosahexaenoic acid level predicts prognosis of renal cell carcinoma. Mol Clin Oncol (2016) 0.75
Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells. Exp Ther Med (2017) 0.75
[Novel biomarkers in renal cell carcinoma : Identification and functional characterization]. Pathologe (2015) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer (2008) 4.42
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res (2005) 3.74
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer (2007) 3.00
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol (2012) 2.56
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2011) 2.05
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int (2010) 1.84
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (2005) 1.78
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol (2007) 1.68
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res (2012) 1.67
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol (2011) 1.56
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res (2011) 1.52
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res (2011) 1.51
Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res (2010) 1.42
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol (2012) 1.31
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res (2007) 1.25
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer (2009) 1.21
The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer (2010) 1.10
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer (2012) 1.07
Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol (2007) 0.98
Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer (2009) 0.95
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol (2010) 1.12
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol (2011) 1.10
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol (2014) 1.03
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol (2006) 0.89
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Ann Oncol (2011) 0.81
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.81
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol (2013) 0.80
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer (2013) 0.79
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol (2006) 0.78
The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer (2013) 0.78
Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol (2017) 0.75